公开(公告)号：US20230181704A1

公开(公告)日：2023-06-15

申请号：US17045538

申请日：2020-07-03

申请人： Alexandre Vasilievich Ivachtchenko ,  Andrey Alexandrovich Ivashchenko ,  Nikolay Filippovich Savchuk ,  Alena Alexandrovna Ivachtchenko ,  Vladimir Grigorievich Loginov ,  Mikhail Topr

发明人： Alexandre Vasilievich Ivachtchenko ,  Andrey Alexandrovich Ivashchenko ,  Nikolay Filippovich Savchuk ,  Alena Alexandrovna Ivachtchenko ,  Vladimir Grigorievich Loginov ,  Mikhail Topr

IPC分类号： A61K38/57 ,  A61K47/02 ,  A61K47/10 ,  A61K47/44 ,  A61P31/14

CPC分类号： A61K38/57 ,  A61K47/02 ,  A61K47/10 ,  A61K47/44 ,  A61P31/14

摘要： This invention relates to a novel anti-SARS-CoV-2 virus agent Antiprovir to be used for the prevention and treatment of coronavirus disease COVID-19.
The use of a pharmaceutical composition, including Aprotex®, Gordox® and Aerus®, with aprotinin as the active ingredient and excipients, said pharmaceutical composition being anti-SARS-CoV-2 virus drug Antiprovir to be used for the prevention and treatment of coronavirus disease COVID-19.
The drug Antiprovir for the prevention and treatment of coronavirus disease COVID-19, which is a pharmaceutical composition containing 0.1% wt. ÷ 0.2% wt. aprotinin, optionally 0.2 %wt. ÷ 1.0% wt. excipients, and the rest is water for injection.

公开(公告)号：US20230372458A1

公开(公告)日：2023-11-23

申请号：US18041926

申请日：2020-12-17

申请人： Alexandre Vasilievich IVACHTCHENKO ,  Nikolay Filippovich SAVCHUK ,  Alena Alexandrovna IVACHTCHENKO ,  Vladimir Grigorievich LOGINOV ,  Mikhail TOPR ,  Andrey Alexandrovich IVASHCHENKO

发明人： Alexandre Vasilievich IVACHTCHENKO ,  Nikolay Filippovich SAVCHUK ,  Alena Alexandrovna IVACHTCHENKO ,  Vladimir Grigorievich LOGINOV ,  Mikhail TOPR ,  Andrey Alexandrovich IVASHCHENKO

IPC分类号： A61K38/57 ,  A61K31/4965 ,  A61P31/14

CPC分类号： A61K38/57 ,  A61K31/4965 ,  A61P31/14

摘要： This invention relates to a novel anti-coronavirus agent for COVID-19 (SARS-CoV-2) combination therapy. The agent comprises, in a therapeutically effective amount and ratio, aprotinin (APR) or a medicinal drug based thereon and a SARS-CoV-2 replication inhibitor. The aprotinin-based medicinal drug is preferably selected from the group consisting of Aprotex, Vero-Narcap, Ingitril, Contrykal, Kontrisel, Trasilol®, Ingiprol, Aprotimbin, Gordox®, Contriven, Trascolan, or Aerus. For SARS-CoV-2 replication inhibitor one can use favipiravir (FPV) or Remdesivir (RMD), or a medicinal drug based thereon. The favipiravir-based medicinal drug is preferably selected from the group consisting of Avigan, Favilavir, Avifavir, Coronavir, or Fabiflu. Further, the invention relates to a combination method to treat COVID-19 (SARS-CoV-2) by administering said anti-coronavirus agent to a patient with COVID-19.
The use of the novel anti-coronavirus agent in COVID-19 (SARS-CoV-2) therapy leads to a new, synergistic effect and allows one to significantly reduce the duration of treatment and mitigate the risk of undesirable side effects.